Investment Rating - The industry investment rating is "Overweight," indicating an expected outperformance of the industry index relative to the benchmark by more than 5% over the next six months [173]. Core Insights - The report highlights that the geopolitical tensions between the U.S. and Iran are supporting international oil prices, with Brent and WTI crude oil futures averaging $64.8 and $60.1 per barrel, respectively, showing a slight increase of $0.1 and a decrease of $0.1 from the previous week [2]. - U.S. crude oil production is reported at 13.73 million barrels per day, with a slight decrease of 20,000 barrels per day week-on-week, while active oil rigs increased by 1 to 411 [2]. - The report recommends several companies for investment, including China National Offshore Oil Corporation (CNOOC), China Petroleum & Chemical Corporation (Sinopec), and China National Petroleum Corporation (PetroChina) [3]. Summary by Sections 1. Weekly Oil Data Brief - The report provides a comprehensive overview of weekly oil data, including price trends, inventory levels, production rates, and import/export statistics [5][7][8]. 2. Oil and Petrochemical Sector Performance - The oil and petrochemical sector has shown varied performance, with specific companies experiencing significant fluctuations in stock prices over the past week, month, and year [21][22]. 3. Crude Oil Data Tracking - Crude oil prices have been tracked, showing fluctuations in both Brent and WTI prices, alongside inventory levels and production data [25][26][37]. - U.S. crude oil inventories have increased, with total inventories reported at 840 million barrels, reflecting a week-on-week increase of 441,000 barrels [2][44]. 4. Refined Oil Data Tracking - The report details refined oil prices, inventory levels, production, and consumption trends, indicating a decrease in refinery throughput to 16.6 million barrels per day, down by 350,000 barrels per day [4][74]. - Refined oil inventories have also seen changes, with gasoline and diesel inventories increasing by 598,000 and 335,000 barrels, respectively [2][108]. 5. Oil Service Sector Data Tracking - The oil service sector is analyzed, focusing on the average day rates for drilling rigs and the overall performance of service companies [158][161].

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology sector, specifically highlighting companies like Yuyuan Pharmaceutical and CanSino Biologics for their promising developments in mRNA vaccines [1]. Core Insights - The mRNA vaccine sector is experiencing a breakthrough, with mRNA technology leading the shift towards efficient and personalized immunotherapy. This technology offers three core competitive advantages: rapid production capabilities, enhanced safety profiles, and flexibility in antigen design, which supports personalized treatment approaches [1][4]. - The report identifies a favorable ranking of sub-industries, with innovative drugs, research services, and CXO services being prioritized for investment. High-yield sectors include traditional Chinese medicine and pharmacies [10][11]. - Specific companies are recommended for investment based on various therapeutic angles, including PD1 PLUS, ADC, and small nucleic acids, with notable mentions such as Innovent Biologics, CanSino Biologics, and Yuyuan Pharmaceutical [10][12][13]. Summary by Sections Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 6.66%, outperforming the CSI 300 index by 5.10%. The Hang Seng Biotechnology Index has also seen a 12.40% increase [4][9]. - Sub-sectors such as pharmaceutical commerce (+4.26%) and raw materials (+2.41%) have performed well, while bioproducts and chemical pharmaceuticals have faced declines [4][9]. Clinical Developments - Corcept Therapeutics has reported positive results from its Phase III trial for relacorilant, indicating survival benefits for patients with platinum-resistant ovarian cancer. Meanwhile, Maiwei Biologics has initiated its first patient dosing in the U.S. for its CDH17-ADC innovative drug [1][4]. Investment Recommendations - The report suggests a diversified investment approach across various therapeutic areas, including: - PD1 PLUS: Focus on companies like 3SBio and Innovent Biologics - ADC: Companies such as InnoCare Pharma and Kintor Pharmaceutical - Small nucleic acids: Recommendations include Frontier Biotechnologies and Yuyuan Pharmaceutical - Traditional Chinese medicine: Companies like Zhaoke Pharmaceutical and Fangsheng Pharmaceutical are highlighted [10][12][13]. Fund Holdings - The report notes a decrease in the proportion of public fund holdings in the pharmaceutical sector, with a total holding of 6.67% as of Q4 2025, down 1.46 percentage points from the previous quarter [17][18]. Company Performance - Specific companies have been highlighted for their market performance, with notable increases in stock prices for companies like *ST Changyao (+70.37%) and Hualan Biological (+32.21%) [9]. This comprehensive analysis provides insights into the current state and future potential of the pharmaceutical and biotechnology industry, emphasizing the importance of mRNA technology and strategic investment in key companies.

Investment Rating - The report maintains an "Overweight" rating for the retail industry [1] Core Insights - Mingming Hen Mang is the largest leisure food and beverage retail chain in China, formed by the merger of "Snacks Are Busy" and "Zhao Yiming Snacks" in November 2023, aiming to address industry pain points through scale procurement and efficient turnover [4][9] - The company is projected to achieve a revenue of CNY 39.34 billion and a net profit of CNY 0.83 billion in 2024, with nearly 15,000 stores [4][10] - The leisure food industry is experiencing rapid growth, with Mingming Hen Mang's revenue increasing from CNY 4.286 billion in 2022 to CNY 39.344 billion in 2024, representing a year-on-year growth of 282.17% [10][13] - The gross margin is expected to improve from 7.45% in 2022 to 9.73% in Q1-Q3 2025, while the net profit margin is projected to rise from 1.67% to 3.36% in the same period [10][16] - The report highlights the acceleration of brand consolidation in the snack retail sector, with the top five chain retailers contributing CNY 2.1 trillion in GMV, accounting for 57.1% of the food and beverage industry [17][20] Summary by Sections Industry Trends - The retail sector is witnessing a significant increase in store numbers, with major players like Mingming Hen Mang and Wancheng Group expanding aggressively across the country [23] - The competitive landscape is stabilizing with Mingming Hen Mang and Wancheng Group leading the market, holding over 70% of the market share in the snack retail sector [17][23] Financial Performance - Mingming Hen Mang's revenue and net profit for 2022, 2023, and 2024 are reported as follows: CNY 4.286 billion, CNY 10.295 billion, and CNY 39.344 billion for revenue; CNY 0.72 billion, CNY 2.17 billion, and CNY 8.34 billion for net profit, respectively [10][13] - The company achieved a revenue of CNY 46.371 billion in Q1-Q3 2025, surpassing the total revenue of 2024, with a year-on-year growth of 75.21% [10][13] Market Position - In 2024, Mingming Hen Mang's GMV reached CNY 55.5 billion, securing a market share of 1.5%, making it the largest leisure food and beverage retail chain in China [17][20] - The report suggests that investors should actively consider opportunities in the snack retail sector, especially with Mingming Hen Mang's upcoming H-share listing on January 28 [17][24]

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology industry, specifically highlighting companies such as Yuyuan Pharmaceutical and CanSino Biologics for potential investment opportunities [1]. Core Insights - The mRNA vaccine sector is experiencing significant advancements, with mRNA technology leading the shift towards efficient and personalized immunotherapy. This technology offers three main competitive advantages: rapid production capabilities, enhanced safety profiles, and flexibility in antigen design, which supports tailored treatments for cancer patients [1][4]. - The report identifies promising sub-sectors within the industry, ranking them as follows: innovative drugs, research services, CXO, traditional Chinese medicine, medical devices, and pharmacies. It suggests a focus on high-growth areas such as innovative drugs, particularly in small nucleic acid therapies, and high-dividend sectors like traditional Chinese medicine and pharmacies [10][11]. Summary by Sections Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 6.66%, outperforming the CSI 300 index by 5.10%. The Hang Seng Biotechnology Index has also seen a year-to-date rise of 12.40% [4][9]. - Notable performers in the market include *ST Changyao (+70.37%) and Hualan Biological (+32.21%) for the week, while the worst performers include Kain Technology (-13.83%) and Aidi Pharmaceutical (-13.70%) [9]. Clinical Developments - Corcept Therapeutics has reported positive results from its Phase III trial for relacorilant, which shows survival benefits for patients with platinum-resistant ovarian cancer. Additionally, Maiwei Biologics has initiated its first patient dosing in the U.S. for its CDH17-ADC innovative drug targeting advanced colorectal and gastrointestinal tumors [4]. Investment Recommendations - Specific companies to watch include: - From the PD1 PLUS perspective: 3SBio, Kanyin Biologics, Innovent Biologics, and Zai Lab [11]. - From the ADC perspective: InnoCare Pharma, Kelun-Biotech, and Baillie Gifford [11]. - From the small nucleic acid perspective: Frontier Biotechnologies, Fuyuan Pharmaceutical, and Yuyuan Pharmaceutical [11]. - From the self-immune perspective: Kangnuo Pharmaceutical, Yifang Biologics, and Yipinhong [11]. - From the innovative drug leaders: BeiGene and HengRui Medicine [11]. - From the CXO and upstream research services: WuXi AppTec, Haoyuan Pharmaceutical, and Aopumai [11]. - From the medical device sector: United Imaging Healthcare and Yuyue Medical [11].

Macro Strategy - The report highlights the investment value of the GF CSI Media ETF (512980.SH), which is closely tracking the CSI Media Index (399971.SZ) and has a management fee of 0.5% per year and a custody fee of 0.1% per year. As of January 16, 2026, the ETF has a circulation scale of 10.759 billion yuan and an annualized return of 29.47% with a volatility ratio of 0.89, indicating reasonable risk control capabilities [1][12] - The underlying index focuses on AI applications, with a significant weight of 31.43% in GEO concept stocks, including key companies like BlueFocus, Yanshan Technology, and Kunlun Wanwei. The top ten weighted stocks account for 51.52% of the index, indicating a high concentration of component stocks [1][12] - The report emphasizes that the current media bull market is driven by AI technology transformation and the assetization of data factors, contrasting with the previous bull market driven by mobile internet traffic. The media sector's valuation is at a historical low, providing a high margin of safety for investors [1][12] Non-Bank Financial Industry - The report indicates that the non-bank financial sector is experiencing an upward trend in market conditions, with public fund holdings in the sector increasing to 2.42% by the end of 2025, up 0.82 percentage points from the previous quarter. However, the sector remains underweight compared to the market [5][16] - The report recommends key stocks such as China Life, Ping An, New China Life, China Pacific Insurance, and CITIC Securities, highlighting their potential to benefit from the improving market environment [5][16] - The average daily trading volume of equity funds reached 34.444 trillion yuan, a year-on-year increase of 155%, indicating a significant improvement in market activity [5][16] Real Estate Industry - The report notes that the real estate market is gradually stabilizing, with a narrowing decline in sales and construction metrics compared to 2024. The total development investment in 2025 was 8.3 trillion yuan, down 17.2% year-on-year, while the new construction area was 5.9 million square meters, down 20.4% [6][18][19] - Sales figures show a cumulative sales area of 8.8 million square meters, down 8.7% year-on-year, with a cumulative sales amount of 8.4 trillion yuan, down 12.6%. The decline in sales is narrowing, particularly in first-tier cities [6][18][19] - Investment recommendations include China Resources Land, China Merchants Shekou, and New City Holdings, with a focus on property management companies like China Resources Mixc Life and Greentown Service [6][18][19] Environmental Industry - The report discusses the growth potential of the waste incineration sector, particularly in Southeast Asia and India, where an estimated 500,000 tons per day of waste incineration capacity is expected, corresponding to an investment scale of approximately 250 billion yuan [7][20] - Companies like Weiming Environmental and Sanfeng Environment are highlighted for their overseas expansion and operational stability, with significant revenue increases driven by high electricity prices and processing fees in international markets [7][20] - The report emphasizes the importance of cost control in overseas projects, with potential for significant profit margins compared to domestic projects, particularly in Indonesia where new projects are expected to yield higher returns [7][20]

Market Performance - As of January 23, 2026, the North Exchange A-share index has 290 constituent stocks with an average market capitalization of 3.335 billion yuan[13] - The North Exchange 50 index rose by 2.60% this week, closing at 1588.66 points, while the Shanghai and Shenzhen 300 index fell by 0.62%[13] - The average daily trading volume for North Exchange A-shares reached 26.831 billion yuan, a decrease of 21.36% from the previous week[13] Economic Indicators - China's GDP for 2025 is projected at 140.19 trillion yuan, with a year-on-year growth of 5%[11] - The industrial production growth is primarily driven by high-tech industries, with notable increases in industrial robots (14.7%), new energy vehicles (8.7%), and integrated circuits (12.9%) in 2025[11] Investment Insights - The price-to-earnings (PE) ratios for North Exchange A-shares, ChiNext, Shanghai Main Board, Shenzhen Main Board, and Sci-Tech Innovation Board are 43.45, 43.34, 24.55, 25.51, and 44.65 respectively as of January 23, 2026[24] - The report suggests focusing on stocks with stable growth and valuation potential in the technology sector[24] Risks - Potential policy risks may affect investor sentiment and trading enthusiasm in the North Exchange[25] - Liquidity risks exist due to lower trading volumes compared to other boards, which may negatively impact the market[25] - There is a risk of companies not meeting profit expectations due to external market changes[25]

证券研究报告·公司点评报告·风电设备 明阳智能（601615） 拟发行股份及现金支付收购德华芯片 100% 股权，太空光伏砷化镓/钙钛矿/HJT 三大技 术并驾齐驱 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 28,124 | 27,158 | 35,515 | 38,616 | 43,200 | | 同比（%） | (8.53) | (3.43) | 30.77 | 8.73 | 11.87 | | 归母净利润（百万元） | 376.72 | 346.11 | 772.71 | 2,099.69 | 3,172.53 | | 同比（%） | (89.06) | (8.12) | 123.25 | 171.73 | 51.10 | | EPS-最新摊薄（元/股） | 0.17 | 0.15 | 0.34 | 0.93 | 1.40 | | P/E（现价&最新摊薄） | 129.97 | 141.46 | 63 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company plans to issue shares and cash to acquire 100% of Dehua Chip, which is a leading player in the domestic space photovoltaic power sector. This acquisition will enhance the company's capabilities in high-end compound semiconductor research and development [7] - The company has made significant advancements in photovoltaic technologies, including perovskite, heterojunction, and tandem solar cells, achieving notable efficiency breakthroughs [7] - The earnings forecast has been adjusted downwards for 2025-2027 due to the high proportion of performance from wind farm transfers, with expected net profits of 770 million, 2.1 billion, and 3.17 billion yuan respectively for those years [7] Financial Summary - Total revenue is projected to be 27.16 billion yuan in 2024, increasing to 43.2 billion yuan by 2027, with a compound annual growth rate of 11.87% [1][8] - The net profit attributable to the parent company is expected to recover significantly, with a forecast of 346 million yuan in 2024, rising to 3.17 billion yuan by 2027, reflecting a growth rate of 51.10% [1][8] - The latest diluted EPS is projected to increase from 0.15 yuan in 2024 to 1.40 yuan in 2027, indicating strong earnings growth potential [1][8]

Investment Rating - The report maintains a bullish outlook, focusing on long-term opportunities in cyclical industries [2][24]. Core Viewpoints - The macro timing model for January 2026 scored 0, indicating a 76.92% probability of an increase in the Wande All A Index over the following month, with an average expected gain of 3.18% [24][31]. - The report emphasizes the strong upward momentum in cyclical industries, particularly in non-ferrous metals and chemicals, driven by global macro events [24][25]. - Short-term investments in thematic sectors such as commercial aerospace, AI applications, and space photovoltaics have shown significant rebounds, although caution is advised due to potential volatility from rapid price increases [25][27]. Fund Size Statistics - In the period from January 19 to January 23, 2026, the top three increasing equity ETF types were: thematic index ETFs (59.135 billion), industry index ETFs (7.975 billion), and cross-border industry index ETFs (5.346 billion) [9][10]. - The top three increasing equity ETF products were: power grid equipment ETF (7.326 billion), chemical ETF (5.717 billion), and sci-tech chip ETF (3.953 billion) [10][14]. - The top three increasing equity ETF tracking indices were: segmented chemical index (9.829 billion), power grid equipment thematic index (7.326 billion), and SSH gold stock index (5.251 billion) [18][20]. Market Outlook - The report suggests a positive outlook for the A-share market in January 2026, with a focus on the micro-cap index and the CSI 500 leading the market [24][25]. - Long-term recommendations include a focus on non-ferrous metals and chemicals, with silver prices surpassing the psychological level of 100, indicating potential for further increases [24][25]. - The report anticipates a market characterized by oscillating upward trends, recommending a growth-oriented ETF allocation [67][68].

证券研究报告·固定收益·固收点评 固收点评 20260125 二级资本债周度数据跟踪 （20260119-20260123） [Table_Tag] [Table_Summary] 观点 ◼ 一级市场发行情况： 本周（20260119-20260123）银行间市场及交易所市场无新发行二级资本 债。 ◼ 二级市场成交情况： 本周（20260119-20260123）二级资本债周成交量合计约 3342 亿元，较 上周增加 691 亿元，成交量前三个券分别为 25 中行二级资本债 02BC （443.52 亿元）、25 广发银行二级资本债 01BC（219.80 亿元）和 25 中 行二级资本债 03A（BC）（77.53 亿元）。 分发行主体地域来看，成交量前三为广东省、山西省和山东省，分别约 为 2521 亿元、299 亿元和 147 亿元。 从到期收益率角度来看，截至 1 月 23 日，5Y 二级资本债中评级 AAA-、 AA+、AA 级到期收益率较上周涨跌幅分别为：-2.18BP、-2.84BP、- 3.84BP；7Y 二级资本债中评级 AAA-、AA+、AA 级到期收益率较上周 涨跌幅分别为：-2.72B ...